Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

This study has been completed.
Sponsor:
Information provided by:
Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:
NCT00561704
First received: November 20, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted

November 20, 2007
November 20, 2007
April 2007
Not Provided
GFR, HbA1c and the adiponectin concentration. [ Time Frame: 6 month ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Obese
  • Type 2 Diabetes
  • Diabetic Nephropathy
  • Glucose Metabolism
  • Angiotensin II Type 1 Receptor Blockers
Drug: losartan
losartan, 100mg daily,
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
October 2007
Not Provided

Inclusion Criteria:

  • Type 2 diabetic nephropathy
  • CKD at stage 1~4

Exclusion Criteria:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.
Female
30 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00561704
ADL
Yes
Not Provided
Shanghai Jiao Tong University School of Medicine
Not Provided
Principal Investigator: hui min Jin, MD shanghai No 3 people's hospital
Shanghai Jiao Tong University School of Medicine
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP